转移性恶性黑色素瘤患者BRAF状态不一致性的荟萃分析
该荟萃分析检索PubMed数据库并纳入22项研究,评估原发灶与转移灶之间及转移灶与转移灶之间BRAF状态不一致率。原发灶与转移灶间合并不一致率为13.4%(95%CI:9.2-18.2%),转移灶之间为7.3%(95%CI:3.3-12.6)。作者认为存在临床意义的不一致率,支持黑色素瘤多克隆模型,并提示考虑激酶抑制剂治疗时应对转移灶进行活检以行BRAF分析。
要点
- 原发灶与转移灶间BRAF状态合并不一致率为13.4%(95%CI:9.2-18.2%)。
- 转移灶与转移灶间BRAF状态合并不一致率为7.3%(95%CI:3.3-12.6%)。
- 突变转为野生型与野生型转为突变的患者数相当。
核心结论
- 原发灶与转移灶之间及转移灶与转移灶之间存在临床意义的BRAF状态不一致率。
- 结果支持黑色素瘤多克隆模型,即同一黑色素瘤病灶内共存BRAF状态不同的亚克隆。
- 结果提示考虑激酶抑制剂治疗时需对转移灶进行活检以行后续BRAF分析。
研究设计与样本
- 通过检索PubMed数据库进行文献综述,共识别630项可能相关的研究。
- 排除仅研究病灶内异质性的研究、患者数≤10的研究以及未包含足够数据以计算不一致率的研究。
- 22项研究符合纳入标准并被纳入荟萃分析。
主要发现
- 原发灶与转移灶之间BRAF状态合并不一致率为13.4%(95%CI:9.2-18.2%)。
- 两个转移灶之间BRAF状态合并不一致率为7.3%(95%CI:3.3-12.6%)。
- 肿瘤BRAF状态从突变转为野生型与从野生型转为突变的患者数相当。
临床怎么用
- 作者认为,考虑激酶抑制剂治疗时需对转移灶进行活检以行后续BRAF分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of malignant melanoma is growing rapidly. Approximately half of the cases are BRAF mutated, making treatment with kinase inhibitors a (MEK and BRAF inhibitors) preferred choice in the advanced setting. The vast majority of these patients will benefit from the treatment. It is therefore of vital importance that the BRAF analysis is reliable and reflects the true nature of the tumour. Intraindividual tumour BRAF heterogeneity may exist, and changes of BRAF status over time might occur. We reviewed the literature by searching the PubMed database and 630 potentially relevant studies were identified. Thereafter, studies that investigated intralesional heterogeneity only, studies with ≤10 patients and studies that did not include adequate data to calculate discrepancy rates were excluded. Twenty-two studies met our inclusion criteria and were included in the meta-analysis. The pooled discrepancy rate between primary and metastatic lesions was 13.4% (95% confidence interval [CI]: 9.2-18.2%) while it was 7.3% (95% CI: 3.3-12.6) between two metastatic lesions. The number of patients whose tumoural BRAF status was changed from mutation to wild type and from wild type to mutation, respectively, was comparable. We conclude that a clinically meaningful discrepancy rate in BRAF status both between primary-metastatic and metastatic-metastatic melanoma lesions exists. Our results support the polyclonal model of melanomas in which subclones with different BRAF status co-exist in the same melanoma lesion. In addition, the results indicate a need for biopsy of a metastatic lesion for subsequent BRAF analysis when treatment with kinase inhibitors is considered.
引用
- Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer. 2017. PMID: 28623774. doi:10.1016/j.ejca.2017.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。